Person:
HATİBOĞLU, MUSTAFA AZİZ

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
MUSTAFA AZİZ
Last Name
HATİBOĞLU
Name
Email Address
Birth Date

Filters

20242
Reset filters

Settings

Type: article ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Role of cell-free DNA and extracellular vesicles for diagnosis and surveillance in patients with glioma
    (2024-01-01) Karaçam B.; Elbasan E. B.; Khan I.; Akdur K.; Mahfooz S.; Merve C.; Yusuf C.; Hatiboğlu M. A.; KARAÇAM, BÜŞRA; HATİBOĞLU, MUSTAFA AZİZ
    Objectives: Liquid biopsy can be used to make the diagnosis, to screen treatment response, and to predict the prognosis. Extracellular vesicles (EVs) and cell-free DNA (cfDNA) sources are used as liquid biopsy biomarkers from body fluids such as serum, cerebrospinal fluid, urine, and mucosa. The purpose of this study was to investigate whether EVs and cfDNA are predictive for diagnosis and prognosis in patients with glioma. Methods: cfDNA and EVs levels were measured from 17 glioma patients at three different time intervals (before surgery, 10–14 days after surgery, and at the time of recurrence) and 7 healthy individuals. We investigated whether their level increased in glioma patients. Also, the correlation between clinical outcome and their levels was analyzed. Results: The mean serum cfDNA level in glioma patients was found to be higher compared to that in healthy controls. The difference between cfDNA level before surgery and that at 3 months follow-up was found to be statistically significant. Also, the mean serum EVs level in the glioma patients was found to be significantly higher compared to that in the control group. Discussion: Our results suggested that cfDNA and EVs could be used as diagnostic biomarkers in patients with glioma. cfDNA could be also a possible biomarker for the surveillance of glioma patients. Further studies are warranted to confirm our findings
  • No Thumbnail Available
    PublicationMetadata only
    Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy
    (2024-03-01) HATİBOĞLU M. A.; Akdur K.; Sakarcan A.; SEYİTHANOĞLU M. H.; TÜRK H. M.; Sinclair G.; ÖZTANIR M. N.; HATİBOĞLU, MUSTAFA AZİZ; SEYİTHANOĞLU, MEHMET HAKAN; TÜRK, HACI MEHMET; ÖZTANIR, MUSTAFA NAMIK
    Background: The role of Gamma Knife radiosurgery (GKRS) in recurrent glioblastoma remains unclear. The purpose of this study is to evaluate the effects of GKRS in a group of patients with recurrent glioblastoma, focusing on survival and safety. Methods: Patients undergoing GKRS for recurrent glioblastoma between September 2014 and April 2019 were included in this study. Relevant clinical and radiosurgical data, including GKRS-related complications, were recorded and analyzed. Overall survival (OS), local progression free survival (LPFS) and prognostic factors for outcome were thoroughly evaluated. Results: Fifty-three patients were analyzed (24 female, 29 male). The median age was 50 years (range, 19–78 years). The median GKRS treatment volume was 35.01 cm3 (range, 2.38-115.57 cm3). Twenty patients (38%) were treated with single fraction GKRS, while 33 (62%) were treated with GKRS-based hypofractionated stereotactic radiotherapy (HSRT). The median prescription dose for single fraction GKRS, 3-fractions HSRT and 5-fractions HSRT were 16 Gy (range, 10−20 Gy), 27 Gy (range, 18−33 Gy) and 25 Gy (range, 25−30 Gy), respectively. The median LPFS and OS times were 8.1 months and 11.4 months after GKRS, respectively. HSRT and Bevacizumab were associated with improved LPFS, while HSRT alone was associated with longer OS. Conclusion: Our findings suggested that HRST would likely improve LPFS and OS in definite settings; the addition of Bevacizumab to GKRS was associated with increased rates of local control. No major complications were reported. Further prospective studies are warranted to confirm our findings.